Staphylococcus aureus is major human pathogen causing large variety of infections worldwide. This study carried out to isolate S. aureus from different clinical cases, also detection of MRSA prevalence and VRSA emerge...Staphylococcus aureus is major human pathogen causing large variety of infections worldwide. This study carried out to isolate S. aureus from different clinical cases, also detection of MRSA prevalence and VRSA emergence, in addition to shedding light on strains that have to be multidrug resistance against various antibiotics, The clinical samples were collected from AI-Jumhuory Teaching Hospital patients in Mosul, isolates identification were achieved by conventional procedures including biochemical and physiological tests, and the specific latex agglutination test. The sensitivity pattern achieved by using disk diffusion technique, for MRSA and VRSA detection oxacillin-disk （1 μg） and vancomycin-disk （30 μg） were used respectively. Results revealed, among 17 S. aureus isolates, 7 （41%） were mostly isolated from patients with wound and burn infections. Isolates had high resistance rate against ampicillin （100%） and cefotaxime （81%）, and lower resistance rate against several antibiotics. MRSA was 88% of total isolates, 93.3% of MRSA were multidrug resistance to 3-9 of antibiotics. Six isolates （40%） of MRSA were VRSA. It is concluded that antibiotics other than vancomycin can be used as anti-MRSA agents after a sensitivity test to prevent the prevalence of VRSA, the major cause of this chemotherapy problems maybe irrational and indiscriminate use of broad-spectrum antibiotics.展开更多
Background:Vancomycin resistance(VR)in staphylococci is emerging fast and posing serious health problems as vancomycin is considered the drug of choice for the treatment of methicillin-resistant staphylococcal infecti...Background:Vancomycin resistance(VR)in staphylococci is emerging fast and posing serious health problems as vancomycin is considered the drug of choice for the treatment of methicillin-resistant staphylococcal infections.Much research has been done on vancomycin-resistant Staphylococcus aureus(VRSA)strains infecting humans and animals but little is understood about other vancomycin-resistant staphylococci(VRS).This study was conducted to determine diversity among staphylococcal species causing infections and to know effective antimicrobials for therapeutic intervention for treatment of infections with vancomycin resistant staphylococci.Methods:Antimicrobial susceptibility data of 620 strains of staphylococci isolated from January 2016 to December 2023 from referred clinical samples were retrieved with their host of origin and association with different types of infections in animals,birds and humans from Clinical Epidemiology of the Institute.All isolates were tested for VR through their growing ability on vancomycin-supplemented(6µg mL-1)brain heart infusion agar.Data was analysed in Microsoft Excel.Results:Staphylococci strains(620)belonged to 26 species and 287 vancomycin-resistant.Of the 287 VRS strains detected only 46(16.03%)were VRSA.Irrespective of their origin and association with different ailments VRS strains were more resistant to herbal and conventional antimicrobial than VSS strains.The most effective antibiotics inhibiting≥80%of the staphylococci were tigecycline,imipenem,nitrofurantoin,linezolid and chloramphenicol inhibiting 88%,86%,86%,81%and 81%of the MRS and 92.31%,94.88%,92.25%,89.09%and 86.56%VRS strains,respectively.Among herbal antimicrobials,the most effective herbal compound was carvacrol followed by thyme oil,cinnamledehyde and ajowan oil,inhibiting≥80%of the strains.VR was most common among S.xylosus,S.schleiferi,and S.delphini strains while S.caseolyticus strains had the least probability of having VR.Staphylococci from mastitis cases had the least probability of possessing VR while those from wound infection had the highest probability of having VR.Conclusion:The study revealed that besides S.aureus,25 more species of staphylococci may be infecting animals,birds and humans.VR was more common in S.xylosus,S.schleiferi,S.auricularis,S.delphini and S.hyicus than in S.aureus strains,and of the VRS and MRS strains,83.97%and 83.46%were non-VRSA and non-methicillin-resistant S.aureus,respectively.Imipenem,tigecycline,nitrofurantoin,chloramphenicol,linezolid,meropenem and minocycline may be a better choice for the treatment of infections caused by methicillin as well as vancomycin-resistant staphylococci.展开更多
Multidrug resistant Staphylococcus aureus (MDRS) is a serious threat to hospitalized patients globally and now represents a challenge for public health, as community-acquired infections appear to be on the increase in...Multidrug resistant Staphylococcus aureus (MDRS) is a serious threat to hospitalized patients globally and now represents a challenge for public health, as community-acquired infections appear to be on the increase in both adults and children. S. aureus colonization has been shown to be a risk factor for community-acquired and nosocomial infections. A total of 130 subjects from the community and 100 subjects from health care-related facilities were evaluated for the prevalence of Staphylococcus aureus colonization and to identify risk factors associated with methicillin-resistant S. aureus (MRSA) and vancomycin resistant S. aureus (VRSA) colonization. Among the community subjects, 35.38% had MRSA and 1.53% VRSA colonization. Subjects from health care-related facilities had a lower MRSA colonization rate (17%) than community subjects and the colonization VRSA has not been found. Age was a risk factor for S. aureus colonization, with subjects under age 20 years or between 60 and 80 years showing higher rates of colonization. In conclusion, a high prevalence of MRSA colonization was observed among people with relationship to the hospital setting. The high level of multiple-drug resistance among community MRSA strains in association with the previously reported excessive use of antibiotics highlights the importance of the problem of antibiotic selective pressure. Our results indicate that the spread of both MRSA and VRSA and the transmission of hospital isolates contribute to the high MRSA/VRSA burden in the community.展开更多
Background:Secondary antimicrobial resistance bacterial(AMR)pneumonia could lead to an increase in mortality in COVID-19 patients,particularly of geriatric patients with underlying diseases.The comedication of current...Background:Secondary antimicrobial resistance bacterial(AMR)pneumonia could lead to an increase in mortality in COVID-19 patients,particularly of geriatric patients with underlying diseases.The comedication of current medicines for AMR pneumonia with corticosteroids may lead to suboptimal treatment or toxicities due to drug-drug interactions(DDIs).Objective:This study aimed to propose new promising dosage regimens of photoactivated curcumin when co-administered with corticosteroids for the treatment of antimicrobial resistance(AMR)pneumonia in COVID-19 patients.Methods:A whole-body physiologically-based pharmacokinetic(PBPK)with the simplified lung compartments model was built and verified following standard model verification(absolute average-folding error or AAFEs).The pharmacokinetic properties of photo-activated were assumed to be similar to curcumin due to minor changes in physiochemical properties of compound by photoactivation.The acceptable AAFEs values were within 2-fold.The verified model was used to simulate new regimens for different formulations of photoactivated curcumin.Results:The AAFEs was 1.12-fold.Original formulation(120 mg once-daily dose)or new intramuscular nano-formulation(100 mg with a release rate of 10/h given every 7 days)is suitable for outpatients with MRSA pneumonia to improve patient adherence.New intravenous formulation(2000 mg twice-daily doses)is for hospitalized patients with both MRSA and VRSA pneumonia.Conclusion:The PBPK models,in conjunction with MIC and applied physiological changes in COVID-19 patients,is a potential tool to predict optimal dosage regimens of photo-activated curcumin for the treatment of co-infected AMR pneumonia in COVID-19 patients.Each formulation is appropriate for different patient conditions and pathogens.展开更多
文摘Staphylococcus aureus is major human pathogen causing large variety of infections worldwide. This study carried out to isolate S. aureus from different clinical cases, also detection of MRSA prevalence and VRSA emergence, in addition to shedding light on strains that have to be multidrug resistance against various antibiotics, The clinical samples were collected from AI-Jumhuory Teaching Hospital patients in Mosul, isolates identification were achieved by conventional procedures including biochemical and physiological tests, and the specific latex agglutination test. The sensitivity pattern achieved by using disk diffusion technique, for MRSA and VRSA detection oxacillin-disk （1 μg） and vancomycin-disk （30 μg） were used respectively. Results revealed, among 17 S. aureus isolates, 7 （41%） were mostly isolated from patients with wound and burn infections. Isolates had high resistance rate against ampicillin （100%） and cefotaxime （81%）, and lower resistance rate against several antibiotics. MRSA was 88% of total isolates, 93.3% of MRSA were multidrug resistance to 3-9 of antibiotics. Six isolates （40%） of MRSA were VRSA. It is concluded that antibiotics other than vancomycin can be used as anti-MRSA agents after a sensitivity test to prevent the prevalence of VRSA, the major cause of this chemotherapy problems maybe irrational and indiscriminate use of broad-spectrum antibiotics.
基金supported by grants received from CAAST-ACLH(NAHEP/CAAST/2018-19)ICAR-World Bank-funded National Agricultural Higher Education Project(NAHEP).
文摘Background:Vancomycin resistance(VR)in staphylococci is emerging fast and posing serious health problems as vancomycin is considered the drug of choice for the treatment of methicillin-resistant staphylococcal infections.Much research has been done on vancomycin-resistant Staphylococcus aureus(VRSA)strains infecting humans and animals but little is understood about other vancomycin-resistant staphylococci(VRS).This study was conducted to determine diversity among staphylococcal species causing infections and to know effective antimicrobials for therapeutic intervention for treatment of infections with vancomycin resistant staphylococci.Methods:Antimicrobial susceptibility data of 620 strains of staphylococci isolated from January 2016 to December 2023 from referred clinical samples were retrieved with their host of origin and association with different types of infections in animals,birds and humans from Clinical Epidemiology of the Institute.All isolates were tested for VR through their growing ability on vancomycin-supplemented(6µg mL-1)brain heart infusion agar.Data was analysed in Microsoft Excel.Results:Staphylococci strains(620)belonged to 26 species and 287 vancomycin-resistant.Of the 287 VRS strains detected only 46(16.03%)were VRSA.Irrespective of their origin and association with different ailments VRS strains were more resistant to herbal and conventional antimicrobial than VSS strains.The most effective antibiotics inhibiting≥80%of the staphylococci were tigecycline,imipenem,nitrofurantoin,linezolid and chloramphenicol inhibiting 88%,86%,86%,81%and 81%of the MRS and 92.31%,94.88%,92.25%,89.09%and 86.56%VRS strains,respectively.Among herbal antimicrobials,the most effective herbal compound was carvacrol followed by thyme oil,cinnamledehyde and ajowan oil,inhibiting≥80%of the strains.VR was most common among S.xylosus,S.schleiferi,and S.delphini strains while S.caseolyticus strains had the least probability of having VR.Staphylococci from mastitis cases had the least probability of possessing VR while those from wound infection had the highest probability of having VR.Conclusion:The study revealed that besides S.aureus,25 more species of staphylococci may be infecting animals,birds and humans.VR was more common in S.xylosus,S.schleiferi,S.auricularis,S.delphini and S.hyicus than in S.aureus strains,and of the VRS and MRS strains,83.97%and 83.46%were non-VRSA and non-methicillin-resistant S.aureus,respectively.Imipenem,tigecycline,nitrofurantoin,chloramphenicol,linezolid,meropenem and minocycline may be a better choice for the treatment of infections caused by methicillin as well as vancomycin-resistant staphylococci.
文摘Multidrug resistant Staphylococcus aureus (MDRS) is a serious threat to hospitalized patients globally and now represents a challenge for public health, as community-acquired infections appear to be on the increase in both adults and children. S. aureus colonization has been shown to be a risk factor for community-acquired and nosocomial infections. A total of 130 subjects from the community and 100 subjects from health care-related facilities were evaluated for the prevalence of Staphylococcus aureus colonization and to identify risk factors associated with methicillin-resistant S. aureus (MRSA) and vancomycin resistant S. aureus (VRSA) colonization. Among the community subjects, 35.38% had MRSA and 1.53% VRSA colonization. Subjects from health care-related facilities had a lower MRSA colonization rate (17%) than community subjects and the colonization VRSA has not been found. Age was a risk factor for S. aureus colonization, with subjects under age 20 years or between 60 and 80 years showing higher rates of colonization. In conclusion, a high prevalence of MRSA colonization was observed among people with relationship to the hospital setting. The high level of multiple-drug resistance among community MRSA strains in association with the previously reported excessive use of antibiotics highlights the importance of the problem of antibiotic selective pressure. Our results indicate that the spread of both MRSA and VRSA and the transmission of hospital isolates contribute to the high MRSA/VRSA burden in the community.
基金supported by postdoctoral fellowship,Thammasat University(Rangsit Campus),ThailandKesara Na-Bangchang was received funding from Thammasat University under the project Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma(No.1/2556,dated October 12,2013)+1 种基金the National Research Council of Thailand(No.45/2561,dated September 10,2018)Kesara Na-Bangchang is supported by the National Research Council of Thailand under the Research Team Promotion grant(grant number NRCT 820/2563,dated November 12,2020).
文摘Background:Secondary antimicrobial resistance bacterial(AMR)pneumonia could lead to an increase in mortality in COVID-19 patients,particularly of geriatric patients with underlying diseases.The comedication of current medicines for AMR pneumonia with corticosteroids may lead to suboptimal treatment or toxicities due to drug-drug interactions(DDIs).Objective:This study aimed to propose new promising dosage regimens of photoactivated curcumin when co-administered with corticosteroids for the treatment of antimicrobial resistance(AMR)pneumonia in COVID-19 patients.Methods:A whole-body physiologically-based pharmacokinetic(PBPK)with the simplified lung compartments model was built and verified following standard model verification(absolute average-folding error or AAFEs).The pharmacokinetic properties of photo-activated were assumed to be similar to curcumin due to minor changes in physiochemical properties of compound by photoactivation.The acceptable AAFEs values were within 2-fold.The verified model was used to simulate new regimens for different formulations of photoactivated curcumin.Results:The AAFEs was 1.12-fold.Original formulation(120 mg once-daily dose)or new intramuscular nano-formulation(100 mg with a release rate of 10/h given every 7 days)is suitable for outpatients with MRSA pneumonia to improve patient adherence.New intravenous formulation(2000 mg twice-daily doses)is for hospitalized patients with both MRSA and VRSA pneumonia.Conclusion:The PBPK models,in conjunction with MIC and applied physiological changes in COVID-19 patients,is a potential tool to predict optimal dosage regimens of photo-activated curcumin for the treatment of co-infected AMR pneumonia in COVID-19 patients.Each formulation is appropriate for different patient conditions and pathogens.
